Pacific Biosciences of California - PACB Stock Forecast, Price & News

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pacific Biosciences of California in the last year. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PACB shares.
View PACB analyst ratings or view top-rated stocks.

6 brokerages have issued 1 year price targets for Pacific Biosciences of California's stock. Their PACB share price forecasts range from $8.00 to $40.00. On average, they predict the company's stock price to reach $15.71 in the next twelve months. This suggests a possible upside of 39.9% from the stock's current price.
View analysts price targets for PACB or view top-rated stocks among Wall Street analysts.

Pacific Biosciences of California's stock was trading at $8.18 at the beginning of 2023. Since then, PACB shares have increased by 37.3% and is now trading at $11.23.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our PACB earnings forecast.

Pacific Biosciences of California will be holding an earnings conference call on Thursday, February 16th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.

Pacific Biosciences of California, Inc. (NASDAQ:PACB) posted its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.01. The biotechnology company had revenue of $34.89 million for the quarter, compared to the consensus estimate of $32.93 million. Pacific Biosciences of California had a negative net margin of 218.44% and a negative trailing twelve-month return on equity of 42.03%. During the same quarter in the previous year, the firm earned ($0.14) EPS.

Pacific Biosciences of California updated its fourth quarter 2022 earnings guidance on Monday, January, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $27.30 million-$27.30 million, compared to the consensus revenue estimate of $27.88 million.

2 employees have rated Pacific Biosciences of California Chief Executive Officer Christian Henry on Glassdoor.com. Christian Henry has an approval rating of 100% among the company's employees. This puts Christian Henry in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacific Biosciences of California investors own include Pfizer (PFE), Gilead Sciences (GILD), Illumina (ILMN), Novavax (NVAX), Advanced Micro Devices (AMD), AT&T (T), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Invitae (NVTA) and Tesla (TSLA).

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

Pacific Biosciences of California's stock is owned by a number of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (11.36%), Sumitomo Mitsui Trust Holdings Inc. (6.27%), Bourne Lent Asset Management Inc. (0.26%), Simplex Trading LLC (0.00%), State of New Jersey Common Pension Fund D (0.10%) and New York State Common Retirement Fund (0.08%). Insiders that own company stock include Christian O Henry, Eric Schaefer, James Michael Phillips, Kathy Ordonez, Lucy Shapiro, Michael Hunkapiller, Oene Mark Van, Peter Fromen, Susan G Kim, Susan K Barnes and William W Ericson.
View institutional ownership trends.

Shares of PACB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PACB stock can currently be purchased for approximately $11.23.

Pacific Biosciences of California (NASDAQ:PACB) has a market capitalization of $2.54 billion and generates $136.97 million in revenue each year. The biotechnology company earns $-181,220,000.00 in net income (profit) each year or ($1.34) on an earnings per share basis.

The company employs 728 workers across the globe.

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The official website for the company is www.pacb.com. The biotechnology company can be reached via phone at (650) 521-8000, via email at ir@pacb.com, or via fax at 302-636-5454.